132 related articles for article (PubMed ID: 38012082)
1. Association between immune-related adverse events and prognosis in patients treated with immune checkpoint inhibitors in melanoma: A surrogacy analysis.
Euvrard R; Robert M; Mainbourg S; Dalle S; Lega JC
Fundam Clin Pharmacol; 2024 Apr; 38(2):369-379. PubMed ID: 38012082
[TBL] [Abstract][Full Text] [Related]
2. Histological diagnosis of immune checkpoint inhibitor induced acute renal injury in patients with metastatic melanoma: a retrospective case series report.
Hultin S; Nahar K; Menzies AM; Long GV; Fernando SL; Atkinson V; Cebon J; Wong MG
BMC Nephrol; 2020 Sep; 21(1):391. PubMed ID: 32894101
[TBL] [Abstract][Full Text] [Related]
3. Systematic review and meta-analysis efficacy and safety of immune checkpoint inhibitors in advanced melanoma patients with anti-PD-1 progression: a systematic review and meta-analysis.
Alrabadi NN; Abushukair HM; Ababneh OE; Syaj SS; Al-Horani SS; Qarqash AA; Darabseh OA; Al-Sous MM; Al-Aomar SR; Ahmed YB; Haddad R; Al Qarqaz FA
Clin Transl Oncol; 2021 Sep; 23(9):1885-1904. PubMed ID: 33877531
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of immune checkpoint inhibitors in patients with anorectal melanoma in association with immune-related adverse events: a case series.
Yokoyama R; Sato Y; Nakamura F; Kagemoto K; Mitsui Y; Okamoto K; Kawano Y; Sogabe M; Miyamoto H; Takayama T
Clin J Gastroenterol; 2023 Dec; 16(6):842-847. PubMed ID: 37632658
[TBL] [Abstract][Full Text] [Related]
5. Adverse events during immunotherapy in Slovenian patients with metastatic melanoma reveal a positive correlation with better treatment outcomes.
Mesti T; Ceplak Mencin V; Mileva Boshkoska B; Ocvirk J
Radiol Oncol; 2021 May; 55(3):354-361. PubMed ID: 33939899
[TBL] [Abstract][Full Text] [Related]
6. Immune-related adverse events correlate with improved survival in patients with advanced mucosal melanoma treated with nivolumab: A single-center retrospective study in Japan.
Otsuka M; Sugihara S; Mori S; Hamada K; Sasaki Y; Yoshikawa S; Kiyohara Y
J Dermatol; 2020 Apr; 47(4):356-362. PubMed ID: 31984569
[TBL] [Abstract][Full Text] [Related]
7. Pituitary dysfunction induced by immune checkpoint inhibitors is associated with better overall survival in both malignant melanoma and non-small cell lung carcinoma: a prospective study.
Kobayashi T; Iwama S; Yasuda Y; Okada N; Okuji T; Ito M; Onoue T; Goto M; Sugiyama M; Tsunekawa T; Takagi H; Hagiwara D; Ito Y; Suga H; Banno R; Yokota K; Hase T; Morise M; Hashimoto N; Ando M; Fujimoto Y; Hibi H; Sone M; Ando Y; Akiyama M; Hasegawa Y; Arima H
J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32606047
[TBL] [Abstract][Full Text] [Related]
8. Prevalence, clinical course, and predictive factors of immune checkpoint inhibitor monotherapy-associated hepatitis in Japan.
Kitagataya T; Suda G; Nagashima K; Katsurada T; Yamamoto K; Kimura M; Maehara O; Yamada R; Shigesawa T; Suzuki K; Nakamura A; Ohara M; Umemura M; Kawagishi N; Nakai M; Sho T; Natsuizaka M; Morikawa K; Ogawa K; Ohnishi S; Komatsu Y; Hata H; Takeuchi S; Abe T; Sakakibara-Konishi J; Teshima T; Homma A; Sakamoto N
J Gastroenterol Hepatol; 2020 Oct; 35(10):1782-1788. PubMed ID: 32187734
[TBL] [Abstract][Full Text] [Related]
9. Immune Checkpoint Inhibitors and Immune-Related Adverse Events in Patients With Advanced Melanoma: A Systematic Review and Network Meta-analysis.
Chang CY; Park H; Malone DC; Wang CY; Wilson DL; Yeh YM; Van Boemmel-Wegmann S; Lo-Ciganic WH
JAMA Netw Open; 2020 Mar; 3(3):e201611. PubMed ID: 32211869
[TBL] [Abstract][Full Text] [Related]
10. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
11. Biologic subtypes of melanoma predict survival benefit of combination anti-PD1+anti-CTLA4 immune checkpoint inhibitors versus anti-PD1 monotherapy.
Rose AAN; Armstrong SM; Hogg D; Butler MO; Saibil SD; Arteaga DP; Pimentel Muniz T; Kelly D; Ghazarian D; King I; Kamil ZS; Ross K; Spreafico A
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33483342
[TBL] [Abstract][Full Text] [Related]
12. Incidence of thromboembolism in patients with melanoma on immune checkpoint inhibitor therapy and its adverse association with survival.
Sussman TA; Li H; Hobbs B; Funchain P; McCrae KR; Khorana AA
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33436486
[TBL] [Abstract][Full Text] [Related]
13. Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis.
Xu C; Chen YP; Du XJ; Liu JQ; Huang CL; Chen L; Zhou GQ; Li WF; Mao YP; Hsu C; Liu Q; Lin AH; Tang LL; Sun Y; Ma J
BMJ; 2018 Nov; 363():k4226. PubMed ID: 30409774
[TBL] [Abstract][Full Text] [Related]
14. Combination anti-PD1 and ipilimumab therapy in patients with advanced melanoma and pre-existing autoimmune disorders.
Brown LJ; Weppler A; Bhave P; Allayous C; Patrinely JR; Ott P; Sandhu S; Haydon A; Lebbe C; Johnson DB; Long GV; Menzies AA; Carlino MS
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33963010
[TBL] [Abstract][Full Text] [Related]
15. Survival Among Veterans Receiving Steroids for Immune-Related Adverse Events After Immune Checkpoint Inhibitor Therapy.
Van Buren I; Madison C; Kohn A; Berry E; Kulkarni RP; Thompson RF
JAMA Netw Open; 2023 Oct; 6(10):e2340695. PubMed ID: 37906189
[TBL] [Abstract][Full Text] [Related]
16. Immune checkpoint inhibitors-associated risk of immune-related hypothyroidism in older patients with advanced melanoma: a real-world analysis of US SEER-Medicare data.
Almutairi AR; Erstad BL; McBride A; Slack M; Abraham I
Expert Opin Drug Saf; 2021 Apr; 20(4):489-497. PubMed ID: 33445985
[No Abstract] [Full Text] [Related]
17. Early 3+3 Trial Dose-Escalation Phase I Clinical Trial Design and Suitability for Immune Checkpoint Inhibitors.
Rahma OE; Reuss JE; Giobbie-Hurder A; Shoja E Razavi G; Abu-Shawer O; Mehra P; Gupta S; Simon R; Khleif SN
Clin Cancer Res; 2021 Jan; 27(2):485-491. PubMed ID: 33082209
[TBL] [Abstract][Full Text] [Related]
18. Systemic treatments for metastatic cutaneous melanoma.
Pasquali S; Hadjinicolaou AV; Chiarion Sileni V; Rossi CR; Mocellin S
Cochrane Database Syst Rev; 2018 Feb; 2(2):CD011123. PubMed ID: 29405038
[TBL] [Abstract][Full Text] [Related]
19. Risk Factors of Venous Thromboembolic Disease in Cancer Patients Treated with Immune Checkpoint Inhibitor.
le Sève JD; Guédon AF; Bordenave S; Agard C; Connault J; Pistorius MA; Quéreux G; Espitia O
Thromb Haemost; 2023 Nov; 123(11):1049-1056. PubMed ID: 37257835
[TBL] [Abstract][Full Text] [Related]
20. Encephalitis Induced by Immune Checkpoint Inhibitors: A Systematic Review.
Velasco R; Villagrán M; Jové M; Simó M; Vilariño N; Alemany M; Palmero R; Martínez-Villacampa MM; Nadal E; Bruna J
JAMA Neurol; 2021 Jul; 78(7):864-873. PubMed ID: 33720308
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
